Abstract
Prolonged-release (PR) melatonin (Circadin®, Neurim Pharmaceuticals, Tel-Aviv, Israel) is a nonbenzodiazepine licensed to treat primary insomnia in patients aged 55 years and older. It exerts its effects by mimicking endogenous melatonin, a hormone which regulates sleep. PR-melatonin has been shown to be effective in improving quality of sleep and morning alertness. An oral dose of 2 mg once-daily for 3 weeks has generally been well tolerated, and does not cause 'hangover' effects or impair memory and psychomotor skills.
| Original language | English |
|---|---|
| Pages (from-to) | 11-21 |
| Number of pages | 11 |
| Journal | Aging Health |
| Volume | 4 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2008 |
Keywords
- Circadin®
- Insomnia
- Melatonin
- Morning alertness
- Quality of sleep